Targeting cell cycle kinases and kinesins in anticancer drug development. (Q52639097)

5 May 2018

title

Targeting cell cycle kinases and kinesins in anticancer drug development. (English)

1 reference

5 May 2018

author name string

Timothy A Yap

1

1 reference

5 May 2018

L Rhoda Molife

2

1 reference

5 May 2018

Sarah P Blagden

3

1 reference

5 May 2018

S de Bono

4

1 reference

5 May 2018

language of work or name

English

0 references

publication date

1 April 2007

1 reference

5 May 2018

Expert Opinion on Drug Discovery

published in

1 reference

5 May 2018

volume

2

1 reference

5 May 2018

issue

4

1 reference

5 May 2018

page(s)

539-560

1 reference

5 May 2018

cites work

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Drugging cell cycle kinases in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Cyclin F regulates the nuclear localization of cyclin B1 through a cyclin-cyclin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Genetic control of cell size at cell division in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Cytoplasmic control of nuclear behavior during meiotic maturation of frog oocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Formation in vitro of sperm pronuclei and mitotic chromosomes induced by amphibian ooplasmic components

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

G1 phase progression: cycling on cue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Inhibitors of mammalian G1 cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

The role of Cdk7 in CAK function, a retro-retrospective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

21 January 2018

Cdc2 regulatory factors

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

A structural perspective of CTD function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

RNA polymerase II carboxy-terminal domain kinases: emerging clues to their function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Proliferation of cancer cells despite CDK2 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Gene amplification in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

CDK4is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Specific protection against breast cancers by cyclin D1 ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Requirement for CDK4 kinase function in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Small-molecule cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Preclinical and clinical development of cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Cyclin-dependent kinase pathways as targets for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Phase II study of E7070 in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Randomized controlled trial of weight training and lymphedema in breast cancer survivors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Aurora kinases dawn as cancer drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

The cellular geography of aurora kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Regulation of Aurora-A kinase on the mitotic spindle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Aurora A and B kinases as targets for cancer: will they be selective for tumors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Aurora-kinase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Chromosomal passengers: the four-dimensional regulation of mitotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

High expression of Aurora-B/Aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Aurora B expression in normal testis and seminomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Cloning of STK13, a third human protein kinase related to Drosophila aurora and budding yeast Ipl1 that maps on chromosome 19q13.3-ter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Protein kinase profile of sperm and eggs: cloning and characterization of two novel testis-specific protein kinases (AIE1, AIE2) related to yeast and fly chromosome segregation regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Centrosomal kinases, HsAIRK1 and HsAIRK3, are overexpressed in primary colorectal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

A conserved mitotic kinase active at late anaphase-telophase in syncytial Drosophila embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Polo-like kinases: a team that plays throughout mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Targeting polo-like kinase 1 for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

SAK/PLK4 is required for centriole duplication and flagella development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Polo-like kinases and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Polo-like kinase (PLK) expression in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Functional studies on the role of the C-terminal domain of mammalian polo-like kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Restarting the cell cycle when the checkpoint comes to a halt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Mechanism of taxane neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Past and future of the mitotic spindle as an oncology target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Antitumor activity of a kinesin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Monastrol inhibition of the mitotic kinesin Eg5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Activating and silencing the mitotic checkpoint through CENP-E-dependent activation/inactivation of BubR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

CENP-E is essential for reliable bioriented spindle attachment, but chromosome alignment can be achieved via redundant mechanisms in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

DNA damage checkpoints in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Chk1 in the DNA damage response: conserved roles from yeasts to mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Targeting the double-strand DNA break repair pathway as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Targeting the checkpoint kinases: chemosensitization versus chemoprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

New checkpoint blockers begin human trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Never say never. The NIMA-related protein kinases in mitotic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Nek8, a NIMA family kinase member, is overexpressed in primary human breast tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Targeting the cell cycle: a new approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Cdk2 knockout mice are viable

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Targeting cell cycle and apoptosis for the treatment of human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

The interaction of steroids with Rana pipiens oocytes in the induction of maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

On the Regulation and Function of Human Polo-like Kinase 1 (PLK1): Effects of Overexpression on Cell Cycle Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

Polo-like kinase-1 is a target of the DNA damage checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.4.539

21 January 2018

Identifiers

DOI

10.1517/17460441.2.4.539

1 reference

5 May 2018

1 reference

5 May 2018